Alzheimer ’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense
Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.
Source: NYT Health - Category: Consumer Health News Authors: Rebecca Robbins and Pam Belluck Tags: Drugs (Pharmaceuticals) Alzheimer ' s Disease Health Insurance and Managed Care Clinical Trials Biogen Inc Source Type: news
More News: Alzheimer's | Clinical Trials | Health | Health Insurance | Insurance | Managed Care | Medicare | PET Scan | Tax